Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (3): 254-256.DOI: 10.3969/j.issn.1673-8640.2022.03.013
Previous Articles Next Articles
Received:2020-09-09
Revised:2021-07-04
Online:2022-03-30
Published:2022-05-10
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.03.013
| 组别 | 例数 | IL-33/（ng/L） | EOS/（×109/L） | NLR |
|---|---|---|---|---|
| AR组 | 101 | 430.02±97.28 | 0.34±0.10 | 1.13±0.29 |
| 对照组 | 101 | 146.72±35.59 | 0.24±0.08 | 1.76±0.34 |
| t值 | 27.486 | 7.848 | 14.168 | |
| P值 | 0.000 | 0.000 | 0.000 |
| 组别 | 例数 | IL-33/（ng/L） | EOS/（×109/L） | NLR |
|---|---|---|---|---|
| AR组 | 101 | 430.02±97.28 | 0.34±0.10 | 1.13±0.29 |
| 对照组 | 101 | 146.72±35.59 | 0.24±0.08 | 1.76±0.34 |
| t值 | 27.486 | 7.848 | 14.168 | |
| P值 | 0.000 | 0.000 | 0.000 |
| 组别 | 例数 | IL-33/（ng/L） | EOS/（×109/L） | NLR |
|---|---|---|---|---|
| 轻度组 | 67 | 398.20±87.27 | 0.30±0.11 | 1.31±0.22 |
| 重度组 | 34 | 607.70±93.30 | 0.51±0.13 | 1.07±0.30 |
| t值 | 11.138 | 8.521 | 4.568 | |
| P值 | 0.000 | 0.000 | 0.000 |
| 组别 | 例数 | IL-33/（ng/L） | EOS/（×109/L） | NLR |
|---|---|---|---|---|
| 轻度组 | 67 | 398.20±87.27 | 0.30±0.11 | 1.31±0.22 |
| 重度组 | 34 | 607.70±93.30 | 0.51±0.13 | 1.07±0.30 |
| t值 | 11.138 | 8.521 | 4.568 | |
| P值 | 0.000 | 0.000 | 0.000 |
| 组别 | 例数 | IL-33 | EOS | NLR | |||||
|---|---|---|---|---|---|---|---|---|---|
| 治疗前/（ng/L） | 治疗后/（ng/L） | 治疗前/（×109/L） | 治疗后/（×109/L） | 治疗前 | 治疗后 | ||||
| 治疗有效组 | 71 | 433.39±91.10 | 289.38±67.27** | 0.35±0.11 | 0.27±0.09** | 1.12±0.21 | 1.50±0.33** | ||
| 治疗无效组 | 30 | 429.92±94.40 | 340.03±72.20** | 0.32±0.13 | 0.25±0.10* | 1.15±0.19 | 1.32±0.28** | ||
| t值 | 0.173 | 3.383 | 1.185 | 0.987 | 0.674 | 2.614 | |||
| P值 | 0.863 | 0.001 | 0.239 | 0.326 | 0.502 | 0.01 | |||
| 组别 | 例数 | IL-33 | EOS | NLR | |||||
|---|---|---|---|---|---|---|---|---|---|
| 治疗前/（ng/L） | 治疗后/（ng/L） | 治疗前/（×109/L） | 治疗后/（×109/L） | 治疗前 | 治疗后 | ||||
| 治疗有效组 | 71 | 433.39±91.10 | 289.38±67.27** | 0.35±0.11 | 0.27±0.09** | 1.12±0.21 | 1.50±0.33** | ||
| 治疗无效组 | 30 | 429.92±94.40 | 340.03±72.20** | 0.32±0.13 | 0.25±0.10* | 1.15±0.19 | 1.32±0.28** | ||
| t值 | 0.173 | 3.383 | 1.185 | 0.987 | 0.674 | 2.614 | |||
| P值 | 0.863 | 0.001 | 0.239 | 0.326 | 0.502 | 0.01 | |||
| [1] | 李亮, 郎媛媛, 张嘉懿, 等. 天津地区变应性鼻炎患儿吸入性变应原的流行病学特征分析[J]. 中国耳鼻咽喉头颈外科, 2017, 24(3):140-143. |
| [2] | 孙景英, 左先波, 张学军, 等. 白细胞介素33/转硫酶同系物2信号通路与皮肤相关性疾病的研究进展[J]. 国际皮肤性病学杂志, 2017, 43(1):47-49. |
| [3] | 刘永平, 陈蕴光, 郑俊斌, 等. 变应性鼻炎鼻激发后鼻腔分泌物嗜酸性粒细胞增加与血清特异性IgE水平正相关[J]. 细胞与分子免疫学杂志, 2017, 33(1):85-88. |
| [4] | 金国松. 炎性因子、嗜酸性粒细胞在变应性鼻炎患儿中的水平变化及作用机制[J]. 中国眼耳鼻喉科杂志, 2019, 19(3):183-185. |
| [5] | 邱彩霞, 郑健, 林东红, 等. 醒鼻温敏凝胶剂对变应性鼻炎大鼠血清白细胞介素-4、转化生长因子-β1和鼻黏膜嗜酸性粒细胞的影响[J]. 中国中医药信息杂志, 2018, 25(2):47-50. |
| [6] | 中华耳鼻喉头颈外科杂志编辑委员会, 中华医学会耳鼻喉头颈外科学分会. 变应性鼻炎诊断和治疗指南(2015年,天津)[J]. 中华耳鼻咽喉头颈外科杂志, 2016, 18(1):6-24. |
| [7] | 中华耳鼻喉头颈外科杂志编辑委员会, 中华医学会耳鼻喉头颈外科学分会. 变应性鼻炎的诊治原则和推荐方案(2004年,兰州)[J]. 2005, 40(3):166-167. |
| [8] | 徐翔, 何庆文, 肖才文, 等. IL-35抑制炎症反应和T细胞反应性减轻变应性鼻炎的机制研究[J]. 中国免疫学杂志, 2017, 33(9):1386-1391. |
| [9] |
XU F, YU S, QIN M, et al. Hydrogen-rich saline ameliorates allergic rhinitis by reversing the imbalance of Th1/Th2 and up-regulation of CD4+CD25+Foxp3+regulatory T cells,interleukin-10,and membrane-bound transforming growth factor-β in guinea pigs[J]. Inflammation, 2018, 41(1):81-92.
DOI URL |
| [10] | 张婷, 薛飞, 程友. 神经肽在变应性鼻炎治疗中的作用机制[J]. 医学综述, 2017, 23(16):3236-3239. |
| [11] |
GU Z W, WANG Y X, CAO Z W. Neutralization of interleukin-17 suppresses allergic rhinitis symptoms by downregulating Th2 and Th17 responses and upregulating the Treg response[J]. Oncotarget, 2017, 8(14):22361-22369.
DOI URL |
| [12] | 邱前辉. 变应性鼻炎免疫治疗的现状和未来[J]. 临床耳鼻咽喉头颈外科杂志, 2017, 31(1):9-12. |
| [13] |
SHAO Y Y, ZHOU Y M, HU M, et al. The anti-allergic rhinitis effect of traditional Chinese medicine of Shenqi by regulating mast cell degranulation and Th1/Th2 cytokine balance[J]. Molecules, 2017, 22(3):504.
DOI URL |
| [14] | 程雷, 钱俊俊, 田慧琴. 变应性鼻炎研究的若干进展[J]. 山东大学耳鼻喉眼学报, 2017, 31(3):1-3. |
| [15] |
BOUSQUET J, CAIMMI D P, BEDBROOK A, et al. Pilot study of mobile phone technology in allergic rhinitis in European countries:the MASK-rhinitis study[J]. Allergy, 2017, 72(6):857-865.
DOI URL |
| [16] | 贾明辉, 陈晓云, 张悦, 等. 鼻用激素联合氯雷他定或孟鲁司特钠治疗变应性鼻炎的疗效分析[J]. 临床耳鼻咽喉头颈外科杂志, 2017, 31(5):369-373. |
| [17] |
KIM M H, KO Y, AHN J H, et al. Efficacy and safety of So-Cheong-Ryong-Tang in treatment of perennial allergic rhinitis:study protocol for a double-blind,randomised,parallel-group,multicentre trial[J]. BMJ Open, 2017, 7(9):e016556.
DOI URL |
| [18] | 邢志敏, 王梓敬, 李世昌. 重视预防治疗在变应性鼻炎治疗体系中的作用[J]. 临床耳鼻咽喉头颈外科杂志, 2017, 31(1):6-8. |
| [19] | 张丽, 虞成飞, 符健. 重灸治疗变应性鼻炎的疗效观察及对IL-33、EOS的影响[J]. 临床耳鼻咽喉头颈外科杂志, 2021, 40(8):963-967. |
| [20] | ALHARETHY S, BAQAYS A, MESALLAM T A, et al. Correlation between allergic rhinitis and laryngopharyngeal reflux[J]. Biomed Res Int, 2018, 2018:2951928. |
| [21] | 邰旭辉, 龙晓宏, 朱宝玉, 等. 辽宁地区变应性鼻炎流行病学调查及相关危险因素分析[J]. 临床军医杂志, 2017, 45(3):275-277. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
